Literature DB >> 2864857

Nifedipine in combination therapy for chronic hypertension. A review.

L G Ekelund.   

Abstract

Results are presented from a study conducted in twelve male patients with hypertension who were treated during alternating one-month periods with a calcium channel blocker, a beta blocker, or a combination of both drugs. After one month of placebo therapy, the patients received 10 mg of nifedipine three times daily, 100 mg of metoprolol twice daily plus 10 mg of nifedipine three times daily, or 100 mg of metoprolol twice daily during successive periods. Nifedipine monotherapy resulted in a significant decrease in both systolic and diastolic blood pressures at rest and in systolic blood pressure during exercise. Monotherapy with metoprolol also significantly reduced systolic blood pressure during exercise. Combination therapy with the calcium channel blocker and the beta blocker produced a significantly greater decrease in both resting and exercise blood pressures than with either drug alone, with achievement of adequate blood pressure control in all patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864857     DOI: 10.1016/0002-9343(85)90500-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

Review 1.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

2.  The efficacy and tolerability of atenolol, nifedipine, and their combination in the management of hypertension.

Authors:  N N Stanley; J L Thirkettle; M P Varma; H Larkin; I D Heath
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.

Authors:  N N Stanley; J L Thirkettle; M P Varma; H Larkin; I D Heath
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.